First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial
The Lancet. Oncology（2023）
摘要
Regeneron Pharmaceuticals and Sanofi.
更多查看译文
关键词
non-small-cell non-small-cell lung cancer,lung cancer,cemiplimab,first-line,empower-lung,open-label
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要